{"disease":{"id":"malignant-solid-tumour","name":"malignant solid tumour"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07044336","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06304818","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06600022","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":441,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06888830","title":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":374,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT02843204","title":"Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT02923466","title":"Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Vyriad, Inc.","has_results":false},{"nct_id":"NCT01376505","title":"Vaccine Therapy in Treating Patients With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Robert Wesolowski","has_results":false},{"nct_id":"NCT04765462","title":"Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT02857920","title":"Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT01554371","title":"Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT01286896","title":"Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT02853903","title":"Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT01151930","title":"Long-Term Compassionate Use Study for Continued Administration of SCB01A-01","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"SynCore Biotechnology Co., Ltd.","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}